Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments

Document 2026-05482 is a Final Rule published by the Department of Justice in the Federal Register on March 20, 2026, with an effective date of March 20, 2026. On September 30, 2019, the Drug Enforcement Administration (DEA) published the final rule, New Single-Sheet Format for U.S. Official Order Form for Schedule I and II Controlled Substances (DEA Form 222). The final rule implemented a new single sheet format for DEA Form 222 and provided for a two-year transition period to switch from the triplicate form. This technical amendment corrects certain regulations erroneously not amended in the final rule which creates ambiguities. The amendment clarifies that a DEA Form 222 Power of Attorney may only be executed or revoked by a registrant, a partner of the registrant, or an officer of a registrant corporate entity. It resolves ambiguity over who may sign a DEA Form 222 and removes the obsolete transition provision for the triplicate version of DEA Form 222. These are conforming revisions that do not make any substantive changes to the regulations. View the original at https://www.federalregister.gov/documents/2026/03/20/2026-05482/ordering-schedule-i-and-ii-controlled-substances-using-dea-form-222-technical-amendments.

No. Document 2026-05482 is not classified as economically significant under Executive Order 12866. Economically significant rules require OIRA review and are estimated to have impacts of $100 million or more per year.